Silence Therapeutics (SLN) Interest Expenses (2024 - 2025)
Silence Therapeutics (SLN) posted Interest Expenses of $80.4 million for Q4 2025, up 30.87% sequentially from $61.4 million in Q4 2024, and up 30.87% YoY from $61.4 million in Q4 2024.
Silence Therapeutics (SLN) Interest Expenses (2024 - 2025) Analysis & Trends
Silence Therapeutics has reported Interest Expenses for 2 years, with the latest figure at $80.4 million in Q4 2025.
- Quarterly Interest Expenses rose 30.87% year-over-year to $80.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $80.4 million (up 30.87% YoY) and the FY2025 annual result came in at $80.4 million, up 30.87% from the prior year.
- Interest Expenses climbed to $80.4 million in Q4 2025 per SLN's latest filing, from $61.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $80.4 million in Q4 2025 and troughed at $61.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.41 Mn |
| Dec 31, 2025 | 80.41 Mn |
| Dec 31, 2024 | 61.45 Mn |
| Dec 31, 2024 | 61.45 Mn |